ZEROCHol 40 Tablet

Rosuvastatin acts by selectively inhibiting HMG-CoA reductase, the rate-limiting enzyme in cholesterol biosynthesis, leading to decreased cholesterol production in the liver and increased clearance of LDL from the bloodstream. ZEROCHol 40 is prescribed for patients at high risk of cardiovascular events, including those with atherosclerotic cardiovascular disease, familial hypercholesterolemia, and other lipid disorders unresponsive to diet and lifestyle modifications alone.

The medication is administered orally, typically once daily, with or without food. Common adverse effects may include headache, myalgia, abdominal discomfort, and elevated liver enzymes; therefore, periodic monitoring of liver function tests and creatine kinase is recommended during therapy. Contraindications include active liver disease, pregnancy, and hypersensitivity to rosuvastatin.

Patients should be advised to report any unexplained muscle pain or weakness promptly. ZEROCHol 40 Tablet is a valuable therapeutic option for effective lipid management and cardiovascular risk reduction.